Search

everythinglearnresearchcommunity

for

Search:↓

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Ruxolitinib can help regrow hair in severe alopecia areata.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Platelet-rich plasma is a safe and effective treatment for hair loss, with fewer relapses than steroid treatment.

The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Transdermal delivery using a fractional CO2 laser is more effective for treating alopecia areata than injections.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Blocking CCR5 can prevent and improve hair loss in alopecia areata.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Mixing platelet-rich plasma with triamcinolone acetonide can potentially improve hair regrowth in alopecia areata patients.